In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Estimands in practice: Bridging the gap between study objectives and statistical analysis
An article by ICON experts Alan Phillips and Tim Clark which examines the progress that has been made since 2018 when implementing the estimand framework within clinical research.
-
Adapting for the future of oncology
ICON experts Andreas Dreps and Martin Lachs share their thoughts on the future of cancer research and the importance of staying adaptive in PharmaPhorum's 'Future of Oncology 2020' magazine.
-
Navigating complexity in oncology cell and gene therapy clinical trials
This article featured in ClinicalOmics 'Insider's guide to precision medicine 2020' (pages 48 & 49) considers how cell and gene therapies are playing an increasingly important role in treating oncology patients.
-
-
An overview on rare disease research
ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.
-
The potential of activity trackers to bias study results
A thought leadership article authored by Marie McCarthy, Tim Clark and Peter Schueler on the impact of activity trackers on study participants and study endpoints.
-
A conversation with an expert in drug development
Colin Orford, Senior Vice President of Drug Development services at ICON, about finding an effective treatment for COVID-19.
-
Use of televisits in studies and related PV concerns
As a result of the COVID-19 pandemic, televisits are becoming strongly considered as an alternative to on-site face-to-face visits, and as a new approach in virtual decentralised trials. ICON’s Xavier Fournie, a member of the EUCROF Pharmacovigilance Working Group, discusses the potential impact of televisits on pharmacovigilance (PV) processes. As a result of the COVID-19 pandemic, televisits are becoming strongly considered as an alternative to on-site face-to-face visits, and as a new approach in virtual decentralised trials. ICON’s Xavier Fournie, a member of the EUCROF Pharmacovigilance Working Group, discusses the potential impact of televisits on pharmacovigilance (PV) processes.
-
Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance. ICON experts discuss the critical role of patients and advocacy groups in the June issue of Pharmaceutical Market Europe.
-
Virtual Congresses – Facing up to virtual reality
The COVID-19 pandemic has challenged the traditional onsite congress engagement experience and forced pharma to rethink face to face events.
